These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Usefulness of beta hCG as tumor marker in the diagnosis and follow up of patients with ovarian cancer.
    Author: Djurdjevic S, Maksimovic M, Pantelic M, Golubovic A, Curcic A.
    Journal: J BUON; 2011; 16(4):715-21. PubMed ID: 22331727.
    Abstract:
    PURPOSE: To test the possibility of using beta human chorionic gonadotropin (β-hCG) as a tumor marker in ovarian cancer by determining its diagnostic and prognostic value, and see for any relationship between disease stage, histological tumor types and serum and ascitic fluid β-hCG levels, as well as to identify false positive and false negative results. METHODS: This was a prospective study in 60 surgically treated patients with ovarian cancer in the period 2006- 2010. The diagnosis was confirmed postoperatively based on the histopathological findings and the continuous determination of β-hCG serum levels, during the 2 postoperative years at regular quarterly intervals. The obtained results were statistically processed using multivariate analysis. RESULTS: β-hCG showed no reliable diagnostic value in ovarian cancer. A statistically significant difference between serum β-hCG levels and different FIGO stages was noted, but not between β-hCG levels and different histological groups of tumors. There were 10.2% of false positive and 18.9% of false negative results in all measurements. CONCLUSION: The use of β-hCG as a tumor marker for ovarian cancer is justified only in patients with preoperatively high levels in advanced FIGO stages (III and IV), regardless of histological type of tumor.
    [Abstract] [Full Text] [Related] [New Search]